Login

Kaixiong Tao

ORCID: 0009-0001-3479-9776
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
A5035465445
Research Areas
  • Gastrointestinal Tumor Research and Treatment
  • Gastrointestinal disorders and treatments
  • Sarcoma Diagnosis and Treatment
  • Lymphoma Diagnosis and Treatment
  • Cancer, Stress, Anesthesia, and Immune Response
  • Vascular Malformations and Hemangiomas
  • Chemokine receptors and signaling
  • Peptidase Inhibition and Analysis
  • Neuroendocrine Tumor Research Advances

Union Hospital
 2025

Huazhong University of Science and Technology
 2025

Wuhan Union Hospital
 2023

 Clinical Benefit of Avapritinib in KIT-Mutant Gastrointestinal Stromal Tumors: A Post Hoc Analysis of the Phase I NAVIGATOR and Phase I/II CS3007–001 Studies
OPENALEX - Publications 
Michael C. Heinrich Xinhua Zhang Robin L. Jones Suzanne George César Serrano and 15 more Yanhong Deng Sebastian Bauer Shirong Cai Xin Wu Yongjian Zhou Kaixiong Tao Zhichao Zheng Jun Zhang Yuehong Cui Hui Cao Meining Wang Jin Hu Jason Yang Jian Li Lin Shen

Abstract Purpose: The efficacy of the selective KIT/PDGFRA inhibitor avapritinib (300 mg once daily) was explored in patients with non–PDGFRA-mutant gastrointestinal stromal tumors (GISTs) from phase I NAVIGATOR and I/II CS3007–001 trials. Patients Methods: Adults unresectable/metastatic, KIT-only-mutant GISTs progression following ≥1 tyrosine kinase inhibitors (TKIs) were included this post hoc analysis. Baseline mutational status identified tumor plasma. Primary endpoints objective...

10.1158/1078-0432.ccr-23-1861 article EN Clinical Cancer Research 2023-11-30
 Data from Clinical Benefit of Avapritinib in <i>KIT-</i>Mutant Gastrointestinal Stromal Tumors: A <i>Post Hoc</i> Analysis of the Phase I NAVIGATOR and Phase I/II CS3007–001 Studies
OPENALEX - Publications 
Michael C. Heinrich Xinhua Zhang Robin L. Jones Suzanne George César Serrano and 15 more Yanhong Deng Sebastian Bauer Shirong Cai Xin Wu Yongjian Zhou Kaixiong Tao Zhichao Zheng Jun Zhang Yuehong Cui Hui Cao Meining Wang Jin Hu Jason Yang Jian Li Lin Shen

&lt;div&gt;AbstractPurpose:&lt;p&gt;The efficacy of the selective KIT/PDGFRA inhibitor avapritinib (300 mg once daily) was explored in patients with non–&lt;i&gt;PDGFRA&lt;/i&gt;-mutant gastrointestinal stromal tumors (GISTs) from phase I NAVIGATOR and I/II CS3007–001 trials.&lt;/p&gt;Patients Methods:&lt;p&gt;Adults unresectable/metastatic, &lt;i&gt;KIT&lt;/i&gt;-only-mutant GISTs progression following ≥1 tyrosine kinase inhibitors (TKIs) were included this &lt;i&gt;post hoc&lt;/i&gt;...

10.1158/1078-0432.c.7077688.v1 preprint EN 2024-02-16
 Data from Clinical Benefit of Avapritinib in <i>KIT-</i>Mutant Gastrointestinal Stromal Tumors: A <i>Post Hoc</i> Analysis of the Phase I NAVIGATOR and Phase I/II CS3007–001 Studies
OPENALEX - Publications 
Michael C. Heinrich Xinhua Zhang Robin L. Jones Suzanne George César Serrano and 15 more Yanhong Deng Sebastian Bauer Shirong Cai Xin Wu Yongjian Zhou Kaixiong Tao Zhichao Zheng Jun Zhang Yuehong Cui Hui Cao Meining Wang Jin Hu Jason Yang Jian Li Lin Shen

&lt;div&gt;AbstractPurpose:&lt;p&gt;The efficacy of the selective KIT/PDGFRA inhibitor avapritinib (300 mg once daily) was explored in patients with non–&lt;i&gt;PDGFRA&lt;/i&gt;-mutant gastrointestinal stromal tumors (GISTs) from phase I NAVIGATOR and I/II CS3007–001 trials.&lt;/p&gt;Patients Methods:&lt;p&gt;Adults unresectable/metastatic, &lt;i&gt;KIT&lt;/i&gt;-only-mutant GISTs progression following ≥1 tyrosine kinase inhibitors (TKIs) were included this &lt;i&gt;post hoc&lt;/i&gt;...

10.1158/1078-0432.c.7077688 preprint EN 2024-02-16
 Supplementary Figure S1 from Clinical Benefit of Avapritinib in <i>KIT-</i>Mutant Gastrointestinal Stromal Tumors: A <i>Post Hoc</i> Analysis of the Phase I NAVIGATOR and Phase I/II CS3007–001 Studies
OPENALEX - Publications 
Michael C. Heinrich Xinhua Zhang Robin L. Jones Suzanne George César Serrano and 15 more Yanhong Deng Sebastian Bauer Shirong Cai Xin Wu Yongjian Zhou Kaixiong Tao Zhichao Zheng Jun Zhang Yuehong Cui Hui Cao Meining Wang Jin Hu Jason Yang Jian Li Lin Shen

&lt;p&gt;Supplementary Figure S1. Examples of remarkable tumor regression in patients with KIT-only-mutant GIST during treatment avapritinib 300 mg QD.&lt;/p&gt;

10.1158/1078-0432.25232041.v1 preprint EN cc-by 2024-02-16
 Supplementary Figure S1 from Clinical Benefit of Avapritinib in <i>KIT-</i>Mutant Gastrointestinal Stromal Tumors: A <i>Post Hoc</i> Analysis of the Phase I NAVIGATOR and Phase I/II CS3007–001 Studies
OPENALEX - Publications 
Michael C. Heinrich Xinhua Zhang Robin L. Jones Suzanne George César Serrano and 15 more Yanhong Deng Sebastian Bauer Shirong Cai Xin Wu Yongjian Zhou Kaixiong Tao Zhichao Zheng Jun Zhang Yuehong Cui Hui Cao Meining Wang Jin Hu Jason Yang Jian Li Lin Shen

&lt;p&gt;Supplementary Figure S1. Examples of remarkable tumor regression in patients with KIT-only-mutant GIST during treatment avapritinib 300 mg QD.&lt;/p&gt;

10.1158/1078-0432.25232041 preprint EN cc-by 2024-02-16
Coming Soon ...